Karakaxas, DimitriosSioziou, AnnaAravantinos, GerasimosCoker, AhmetPapanikolaou, Ioannis S.Liakakos, TheodorosDervenis, ChristosGazouli, Maria2019-10-272019-10-2720161948-5204https://doi.org/10.4251/wjgo.v8.i6.520https://hdl.handle.net/11454/52651AIM: To evaluate the association between the inter-leukin 1 beta (IL-1 beta) polymorphisms and the pancreatic neuroendocrine tumor (pNET) development. METHODS: A case-control study was conducted analyzing IL-1 beta polymorphisms using germline DNA collected in a population-based case-control study of pancreatic cancer (51 pNET cases, 85 pancreatic ductal adenocarcinoma cases, 19 intraductal papillary mucinous neoplasm and 98 healthy controls). RESULTS: The distribution of genotypes for the -511 C/T polymorphism in the pNET patient groups showed significant difference compared to the control group. It is known that the carriers of the IL-1 beta -511T allele have increased concentrations of IL-1 beta. The -511 CT and TT high-expression genotypes were over-represented in pNET patients. CONCLUSION: The findings of this study suggested a possible role of IL-1 beta -511 C/T genotypes in the pathogenesis of pNETs since the presence of the IL-1 beta -511 CT and TT genotypes and the T allele was associated with an increased risk of pNET only.en10.4251/wjgo.v8.i6.520info:eu-repo/semantics/openAccessInterleukin 1 betaNeuroendocrine tumorsPancreasArticle86520525WOS:00040854300000527326321N/A